Omnicell, Inc (OMCL) Files Form 4 Insider Selling : Jorge R. Taborga Sells 25,979 Shares

Omnicell, Inc (OMCL): Jorge R. Taborga , Executive VP. Engineering of Omnicell, Inc sold 25,979 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $33.00 per share for a total value of $857,307.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 25, 2016, Gary S Petersmeyer (director) sold 6,250 shares at $31.22 per share price.On May 23, 2016, Jorge R. Taborga (Executive VP. Engineering) sold 1,933 shares at $30.73 per share price.Also, On May 23, 2016, Dan S Johnston (EVP-Chief Legal & Admin Off) sold 8,850 shares at $30.73 per share price.On May 10, 2016, J Christopher Drew (Exe VP, Sales & Marketing) sold 15,000 shares at $31.63 per share price.

Shares of Omnicell (OMCL) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.29 points or -0.88% at $32.55 with 1,66,785 shares getting traded. Post opening the session at $32.5, the shares hit an intraday low of $32.4 and an intraday high of $33 and the price vacillated in this range throughout the day. The company has a market cap of $1,169 M and the number of outstanding shares has been calculated to be 3,59,17,793 shares. The 52-week high of Omnicell is $40.8 and the 52-week low is $25.06.

Omnicell Money Flow Index Chart

Company has been under the radar of several Street Analysts.Omnicell is Reiterated by Topeka Capital Markets to Buy while Lowering the Price Target of the company shares to $ 37 from a previous price target of $38 . The Rating was issued on Mar 21, 2016.

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.

Leave a Reply

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.